Questions discussed in this category

Given data presented at ASCO 2020?

Are there specific mutations or co-mutations were you would consider use of this agent? 

1st-line pembrolizumab is supposed to be used AFTER failure of appropriate targeted agents in this setting, but would you consider the reverse sequenc...

The EGFR subgroup appeared not have benefited as much as other patients in the publication. However, recently it was reported that the PACIFIC study m...

Does EGFR+ status influence your decision? What is the significance of this finding and its potential for progression? Is it simply occult disease con...

Papers discussed in this category

The New England journal of medicine, 2015-10-22

The New England journal of medicine, 2016-11-10

J Thorac Oncol,

Clin. Cancer Res., 2015 May 27

Lancet (London, England), 2017-01-21

Lancet (London, England), 2016-04-09

The New England journal of medicine, 2018-06-14

The Lancet. Respiratory medicine, 2019-05

Ann. Oncol.,

The New England journal of medicine, 2018-12-13

J. Clin. Oncol., 2019 Dec 11

Lancet Oncol., 2017 Sep 25

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-12-01